MedTrace Logo

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

NCT04928313 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 368

Last updated 2021-06-16

No results posted yet for this study

Summary

This trial was an obsevational phase IV prospective multicenter study designed to evaluate the safety and effectiveness of Cinnomer® in patients with MS in Iran.

The primary objective of this study was safety assessment of Cinnomer®

Secondary objectives were:

* Effectiveness assessment of Cinnomer®
* Assessment of the patients' QoL
* Evaluation of the patients' depression status

Conditions

Interventions

DRUG

Glatiramer Acetate

Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.

Sponsors & Collaborators

  • Cinnagen

    lead INDUSTRY

Principal Investigators

  • Abdorreza Naser Moghadasi, Assistant Professor · Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-12
Primary Completion
2020-02-17
Completion
2020-02-17

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928313 on ClinicalTrials.gov